Capricor Therapeutics (NASDAQ:CAPR) Earns Buy Rating from HC Wainwright

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $77.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 301.46% from the stock’s previous close.

A number of other research firms have also weighed in on CAPR. Piper Sandler assumed coverage on Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective for the company. Oppenheimer restated an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Cantor Fitzgerald raised their target price on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Maxim Group lifted their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat, Capricor Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Stock Up 13.4 %

Shares of NASDAQ:CAPR traded up $2.27 during midday trading on Thursday, reaching $19.18. The company’s stock had a trading volume of 1,197,743 shares, compared to its average volume of 1,145,519. The firm has a market capitalization of $870.96 million, a PE ratio of -20.80 and a beta of 4.00. The stock has a fifty day moving average of $14.63 and a 200 day moving average of $8.29. Capricor Therapeutics has a twelve month low of $2.87 and a twelve month high of $23.40.

Insider Buying and Selling at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the company’s stock in a transaction dated Friday, September 20th. The stock was acquired at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the acquisition, the insider now directly owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 12.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Capricor Therapeutics

Large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new position in Capricor Therapeutics during the first quarter worth $40,000. SG Americas Securities LLC acquired a new position in shares of Capricor Therapeutics during the 3rd quarter valued at about $133,000. The Manufacturers Life Insurance Company acquired a new position in shares of Capricor Therapeutics during the 3rd quarter valued at about $161,000. FMR LLC purchased a new stake in shares of Capricor Therapeutics in the third quarter valued at about $370,000. Finally, Main Street Financial Solutions LLC increased its position in Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares during the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.